Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
Total Revenue	$ 926,936	$ 1,952,237
Operating Expenses
Cost of Sales	689,281	1,114,550
General and Administrative	2,327,385	2,491,228
Total Operating Expenses	3,016,666	3,605,778
Operating Losses from Operations	(2,089,730)	(1,653,541)
Other Income (Expense)
Interest Income	39,278	172,400
Foreign Exchange Transaction (Loss) Gain	(788,302)	408,095
Unrealized Loss on Securities Investment	(2,484,117)	(395,141)
Unrealized Gain (Loss) on Securities Investment - Related Party	1,296,271	(3,503,874)
Realized Loss on Securities Investment	(131,313)	(3,436,783)
Loss on Investment Securities at Equity Method	(268,276)	(136,380)
Finance Costs		(448,008)
Other Income	103,007	1,284,893
Total Other Expense, Net	(2,233,452)	(6,054,798)
Net Loss Income Before Income Taxes	(4,323,182)	(7,708,339)
Income Tax Expense		(222,114)
Net Loss	(4,323,182)	(7,930,453)
Net Loss Attributable to Non-Controlling Interest	(465,296)	(1,463,167)
Net Loss Attributable to Common Stockholders	(3,857,886)	(6,467,286)
Other Comprehensive Loss, Net
Unrealized Loss on Securities Investment		(9,123)
Foreign Currency Translation Adjustment	1,095,943	(649,140)
Comprehensive Loss	(3,227,239)	(8,588,716)
Comprehensive Loss Attributable to Non-controlling Interests	(305,617)	(1,085,395)
Comprehensive Loss Attributable to Common Stockholders	$ (2,921,622)	$ (7,503,321)
Net Loss Per Share - Basic and Diluted	$ (0.46)	$ (1.30)
Weighted Average Common Shares Outstanding - Basic and Diluted	8,451,048	4,959,233	[1]
Rental [Member]
Revenue
Total Revenue	$ 633,811	$ 232,582
Property [Member]
Revenue
Total Revenue		1,041,524
Biohealth [Member]
Revenue
Total Revenue	12,786	617,471
Other [Member]
Revenue
Total Revenue	$ 280,339	$ 60,660

[1] The numbers of weighted average outstanding common stock - basic and diluted were adjusted retrospectively to reflect 20-for-1 reverse stock split on December 28, 2022